Tuesday, 16 Oct 2018

You are here

Comorbidities Undermine Clinical Outcomes in Psoriatic Arthritis

Analysis of data from the DANBIO registry of psoriatic arthritis (PsA) patients treated with tumor necrosis factor inhibitor (TNFi) therapy shows that comorbidities were associated with higher baseline disease activity, shorter TNFi persistence, and reduced clinical response rates to TNFi.

Investigators studied 1,750 PsA patients and assessed comorbidities using the Charlson Comorbidity Index (CCI). Patients with higher CCI scores were generally older and female, had a longer PsA disease duration, and had a higher BMI compared with patients without comorbidities. Those with higher CCI scores were more likely to have PsA‐related diseases (psoriasis, inflammatory bowel disease, uveitis, and urethritis). A CCI of 2 or higher was seen in 191 patients (9.6%).

Higher levels of comorbidity (higher CCI scores) were associated with: 

  • higher disease activity measures at baseline
  • increased occurrence of depression and/or anxiety
  • shorter TNFi persistence with CCI score ≥2 

These findings are novel and support the importance of monitoring and treating comorbidities in patients with PsA.

Comorbidities are common, but are not commonly dealt with in rheumatology daily practice. The impact of comorbidity has been seen in other recent studies.

Strober and colleagues have also recently reported that PsA patients with metabolic syndrome-related co-morbidities have lower TNFi persistence. (Citation source: http://bit.ly/2Fz9zi7). Switching to a second TNFi was effective in some, but these too had lower TNFi persistence, suggesting the validity of switching to a second TNFi.

Lastly, it is well known that obesity and decreased therapeutic responses are linked. Holgard et al studied 2 different registries and demonstrated that TNFI adherence was shorter in obese patients, especially among men who were obese (P < 0.01 vs non-obese). In multivariable analyses, obesity increased the risk of TNFI withdrawal [hazard ratio 1.6 (95% CI 1.3, 2.0)] and reduced odds for EULAR good or moderate responses [odds ratio 0.47 (95% CI 0.29, 0.72)]. Obesity was associated with higher disease activity and seemed to diminish response and adherence to TNFIs in PsA.

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Apremilast Succeeds in Scalp Psoriasis

Celgene has announced results from the phase 3 STYLE study, showing apremilast yielding significant improvement in moderate-to-severe scalp psoriasis. STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive apremilast 30 mg twice daily or placebo for the first 16 weeks.

Does Gender Make a Difference in Axial Spondyloarthritis

Males and females can both be affected by axial spondyloarthritis (axSpA). A recent study shows that while there are some differences and similarities, HLA-B27 and imaging are still pivotal elements for diagnosis of axSpA in both genders.

Complementary Therapies in Psoriasis

A systematic review in Archives of Dermatology suggests that among complementary and alternative medicine (CAM) therapies, the most effective are indigo naturalis, curcumin, dietary modification, meditation, and acupuncture.

It is estimated that  nearly half of patients with psoriasis report they use CAM, although their benefits are unclear in psoriasis.

Biologic Therapies Improve Work Outcomes in Spondyloarthritis

A study from the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBR-AS) shows that biologic use significantly improves work productivity and overall activity impairment.

 

The BSRBR-AS registry analyzed 577 participants who were employed;  28% were started on biological therapy .

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.